Roxatidine in duodenal ulcer.
J Postgrad Med
;
1995 Jul-Sep; 41(3): 64-5
Artículo
en Inglés
| IMSEAR
| ID: sea-116875
ABSTRACT
Roxatidine acetate is a new H2-receptor antagonist. A randomized double-blind clinical trial in fifty-three patients with endoscopically proven duodenal ulcers > 5 mm in diameter was undertaken to compare safety and efficacy of roxatidine with that of ranitidine. Twenty-six patients received roxatidine (75 mg bid) while 27 patients received ranitidine (150 mg bid) for 4 weeks. One patient in each group did not come for follow up. Roxatidine and ranitidine had comparable ulcer healing rates (22/25 vs 22/26); roxatidine, however, resulted in greater reduction in the number and severity of night time pain episodes (p < 0.05). No adverse event was reported during 4 weeks of treatment with roxatidine. Thus roxatidine achieves the primary therapeutic goal of relief of pain better than ranitidine.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Piperidinas
/
Ranitidina
/
Dimensión del Dolor
/
Femenino
/
Humanos
/
Masculino
/
Esquema de Medicación
/
Método Doble Ciego
/
Estudios de Seguimiento
/
Resultado del Tratamiento
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio observacional
/
Estudio pronóstico
Idioma:
Inglés
Revista:
J Postgrad Med
Año:
1995
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS